Form 4 Filing by Dan Michael Falk for Evogene Ltd.

This filing details a Form 4 submission by Dan Michael Falk, a director at Evogene Ltd., on September 29, 2026. The report pertains to transactions on September 4, 2026, specifically the grant of 2,500 stock options to purchase ordinary shares. The exercise price is NIS 1.75 per share, equivalent to $0.58, based on the exchange rate on the grant date. These options vest quarterly, with full vesting expected by September 4, 2027. The filing also includes a power of attorney granted to Nitsan Deutsch to handle SEC filings related to securities transactions.